Probiotics for Liver Health: Evidence-Based Strains and What the Research Actually Shows
A peer-reviewed look at the gut-liver axis, how probiotics influence liver function, and which strains have the strongest clinical evidence — organized by liver condition
The liver is the body's central metabolic hub — responsible for detoxifying blood from the gut, producing bile, regulating cholesterol and blood sugar, and processing virtually every compound that enters through the digestive tract. What most people don't realize is that liver health is inextricably tied to gut health, and the composition of your gut microbiome is one of the most influential variables in whether your liver stays resilient or begins to accumulate damage over time.
The gut and liver are connected by the portal vein, which carries blood — and whatever is dissolved in it — directly from the intestines to the liver before it ever reaches systemic circulation. This anatomical reality means that when the gut microbiome is disrupted, the liver is the first organ to bear the consequences: endotoxins, inflammatory signals, harmful metabolites, and pathogen-associated molecular patterns all arrive at the liver first.[1]
Over the past decade, research on probiotics and liver disease has expanded substantially. Multiple systematic reviews and meta-analyses now exist for nonalcoholic fatty liver disease (NAFLD), liver cirrhosis, and alcohol-associated liver disease, with consistent themes emerging across all three: probiotics can reduce liver enzyme levels (ALT and AST), attenuate hepatic inflammation, reinforce intestinal barrier integrity, and modulate the dysbiotic microbiome patterns characteristic of liver disease.
This article covers the gut-liver axis, the specific probiotic strains studied for liver health that are present in MicroBiome Restore, and a condition-by-condition breakdown of what the peer-reviewed literature says — including honest caveats about where the evidence is still maturing. If your specific concern is fatty liver disease, we cover the NAFLD evidence in dedicated depth in our companion guide on gut dysbiosis and probiotic restoration — as well as our full article on probiotics for NAFLD, which goes much deeper on fatty liver–specific RCT data, strain dosing for steatosis, and the evidence on fibrosis reversal.
Key Takeaways
- The gut-liver axis is the central pathway. The portal vein delivers gut-derived compounds — including endotoxins, short-chain fatty acids, and microbial metabolites — directly to the liver, making the gut microbiome one of the most important determinants of liver health.[1]
- Gut dysbiosis in liver disease is characterized by depleted Lactobacillus and Bifidobacterium. Across NAFLD, cirrhosis, and alcoholic liver disease, studies consistently find reduced populations of beneficial bacteria and increased pathogenic Proteobacteria and Enterobacteriaceae.[2]
- Probiotics reduce liver enzyme levels. A 2024 meta-analysis of 22 RCTs in cirrhosis found probiotics significantly reduced AST and GGT, and reduced serum ammonia levels — a key driver of hepatic encephalopathy.[3]
- Multi-strain formulas containing Lactobacillus and Bifidobacterium genera consistently outperform single-strain products across liver disease categories, with combinations including L. rhamnosus, L. plantarum, B. longum, B. bifidum, and Streptococcus thermophilus appearing most frequently in positive trials.[4]
- The liver-protective mechanisms of probiotics are well-characterized: enhanced tight junction integrity, reduced LPS translocation, downregulation of the TLR4/NF-κB inflammatory cascade, improved bile acid metabolism, and increased short-chain fatty acid production all converge on reduced hepatic injury.[1]
- Synbiotics — probiotics combined with prebiotic substrates — show the most consistent effects on liver enzymes, steatosis, and inflammation in NAFLD patients, with a 2024 meta-analysis finding significant reductions in ALT (SMD: −0.48), AST (SMD: −0.35), and TNF-α (SMD: −0.86).[5]
- Safety is well established. Lactobacillus, Bifidobacterium, Bacillus species, Streptococcus thermophilus, Pediococcus, and Lactococcus — all represented in MicroBiome Restore — fall within the GRAS (Generally Recognized as Safe) category and demonstrate good tolerability across liver disease populations in RCT data.[6]
Understanding the Gut-Liver Axis
The gut-liver axis describes the bidirectional communication network between the gastrointestinal tract and the liver, mediated primarily by the portal vein. Blood from the intestines drains into the portal circulation and travels directly to the liver, meaning the liver is exposed to virtually everything absorbed from the gut — nutrients, metabolites, microbial products, and toxins alike — before they reach the rest of the body.[1]
In the other direction, the liver sends bile acids and immune factors back into the gut via the bile duct. This bidirectional flow creates a functional loop: the health of the gut microbiome directly influences hepatic immune activity, inflammation, and metabolic function, and the liver's output of bile acids in turn shapes the composition of the gut microbial community.
The Portal Vein: Why the Gut's Output Is the Liver's Input
The gut microbiome produces an enormous range of metabolites — short-chain fatty acids (SCFAs) like butyrate, propionate, and acetate; secondary bile acids; tryptophan derivatives; ethanol; and lipopolysaccharide (LPS). In a healthy gut with an intact mucosal barrier, most harmful compounds are filtered before they can cross the epithelium. But when the gut barrier is compromised — a state often called "leaky gut" — LPS and other pathogen-associated molecular patterns (PAMPs) translocate into the portal blood and reach the liver, where they activate toll-like receptor 4 (TLR4) on Kupffer cells and trigger the NF-κB inflammatory pathway.[1] This mechanism is directly implicated in the progression of NAFLD, steatohepatitis, fibrosis, and cirrhosis.
It follows that restoring the gut microbiome to a healthier composition — more Lactobacillus and Bifidobacterium, fewer pathogenic Proteobacteria — has direct downstream consequences for the liver. Fewer harmful compounds cross the gut barrier, less LPS reaches the portal vein, and the liver's Kupffer cells receive fewer inflammatory signals. This is the foundational logic underpinning probiotic therapy for liver disease, and it is increasingly supported by clinical trial data.
To understand the full scope of what gut dysbiosis means and why it develops, our dedicated article covers the microbial imbalances, triggering factors, and probiotic restoration strategies in depth.
How Gut Dysbiosis Drives Liver Disease
Across every major category of chronic liver disease, the microbial signature is remarkably consistent. A 2025 systematic review including 73 studies found that gut microbial diversity (alpha diversity) is significantly reduced in cirrhotic patients compared to healthy controls, and that the microbiome shifts toward a more pathogenic, pro-inflammatory configuration — with increases in Proteobacteria, Enterococcus, and Streptococcus, and decreases in beneficial genera including Bifidobacterium, Ruminococcus, Faecalibacterium, and Roseburia.[7]
In the context of nonalcoholic fatty liver disease, gut dysbiosis is characterized by a decrease in beneficial bacteria — particularly Lactobacillus and Bifidobacterium — and an increase in pro-inflammatory species such as Escherichia coli and certain Bacteroides strains. This shift leads to increased gut permeability, allowing LPS to enter the portal circulation and activate hepatic TLR4, initiating a cascade of inflammation, de novo lipogenesis, and insulin resistance that drives progression from simple steatosis to steatohepatitis.[1]
In alcohol-associated liver disease, ethanol directly damages intestinal epithelial cells, disrupts tight junction proteins, and creates a favorable environment for Gram-negative bacteria that produce LPS. This endotoxemia — elevated circulating LPS — is a critical driver of alcoholic hepatitis and liver injury. Research has shown that patients with alcohol-related liver injury have significantly lower fecal counts of Bifidobacteria and Lactobacilli compared to healthy controls.[8]
For context on how the microbiome is tested and what specific imbalances look like in practice, our article on Bifidobacterium deficiency and our guide on Lactobacillus deficiency signs and strains cover these patterns in clinical detail.
How Probiotics Protect the Liver: The Mechanisms
The liver-protective mechanisms of probiotics are not speculative — they are well-characterized at the molecular level and increasingly validated in human clinical trials. Multiple pathways operate simultaneously, which is one reason multi-strain formulas tend to show more consistent benefit than single-strain products.
1. Reinforcing the Intestinal Barrier
The most fundamental mechanism is physical: probiotics — particularly Lactobacillus and Bifidobacterium species — enhance the integrity of tight junction proteins (including occludin, claudin, and zonula occludens-1) that seal the spaces between intestinal epithelial cells. When these proteins are intact, LPS and other harmful compounds cannot cross the epithelium into the portal blood. L. plantarum and L. rhamnosus GG have both been shown to enhance antioxidant defenses and restore tight junction function in alcohol-injured intestinal tissue.[9]
2. Reducing LPS Translocation and TLR4 Activation
By displacing pathogenic Gram-negative bacteria that produce LPS, and by reinforcing the barrier that prevents its crossing, probiotic supplementation reduces circulating endotoxin levels. Lower LPS reaching the liver means less TLR4 activation on Kupffer cells, less NF-κB signaling, and reduced production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. This is a central mechanism in multiple liver disease contexts.[1] Notably, L. rhamnosus GG and L. acidophilus have both been shown to directly reduce hepatic TNF and TLR4 expression in experimental models of liver injury.[10]
3. Short-Chain Fatty Acid Production
Probiotic bacteria — particularly when paired with prebiotic substrates — ferment dietary fiber to produce SCFAs including butyrate, propionate, and acetate. These metabolites have direct anti-inflammatory effects in both the gut and the liver, serving as energy substrates for colonocytes (which reduces gut permeability), activating PPAR-α receptors that inhibit lipogenesis, and modulating immune function.[1] This is why the synbiotic approach — probiotics with prebiotic substrates — consistently shows stronger effects on liver outcomes than probiotics alone.
4. Bile Acid Metabolism Modulation
The gut microbiome plays a critical role in secondary bile acid metabolism. Beneficial bacteria including Lactobacillus, Bifidobacterium, and Bacteroides convert primary bile acids into secondary forms that activate the farnesoid X receptor (FXR) and regulate the feedback loop governing bile acid synthesis in the liver. Dysbiosis disrupts this regulation, contributing to lipid accumulation and inflammation in hepatocytes.[1] Probiotic restoration of beneficial bile acid–metabolizing bacteria normalizes this signaling axis.
5. Ammonia Reduction (Cirrhosis Context)
In patients with cirrhosis, the dysbiotic gut microbiome produces excess ammonia — a toxic metabolite that, when the damaged liver cannot adequately process it, reaches the brain and causes hepatic encephalopathy (HE). Probiotics reduce ammonia production by displacing urease-positive bacteria, lowering intestinal pH (which traps ammonia as ammonium ion for fecal excretion), and improving the gut epithelial barrier that limits ammonia absorption.[6]
Key Probiotic Strains in MicroBiome Restore With Liver Health Evidence
The strains below are all present in MicroBiome Restore and represent the species with the strongest peer-reviewed evidence for liver health outcomes. We discuss only strains in our formula — we won't recommend strains we don't include just to pad the content.
Lactobacillus rhamnosus — The Most Extensively Studied Strain
Lactobacillus rhamnosus GG (LGG) is the most frequently studied probiotic in alcohol-associated liver disease, with a well-characterized mechanistic profile and replicated clinical results. LGG reduces plasma endotoxin levels, improves liver enzymes (ALT and AST), and modulates the microbiome toward a more protective composition in multiple animal and human models of liver injury.[9] In pediatric NAFLD, oral supplementation with L. rhamnosus GG was associated with a significant reduction in ALT — a direct marker of hepatocellular injury.[11] Mechanistically, LGG works through intestinal barrier reinforcement, upregulation of hypoxia-inducible factor (HIF) in enterocytes (which strengthens tight junctions under hypoxic stress), and direct downregulation of hepatic TNF-α production.[9] For a detailed review of what this strain does across other health contexts, see our article on Lactobacillus rhamnosus benefits.
Lactobacillus plantarum — Barrier Restorer and Antioxidant Activator
L. plantarum 8PA3 (in combination with Bifidobacterium bifidum) was the focus of one of the earliest human clinical trials in alcohol-induced liver injury, demonstrating a significant end-of-treatment reduction in ALT, AST, GGT, LDH, and total bilirubin compared to standard therapy alone.[8] Beyond the direct enzyme evidence, L. plantarum HFY09 has been shown to enhance liver antioxidant defenses by elevating superoxide dismutase (SOD) and glutathione (GSH) levels — reducing oxidative stress that drives hepatocyte damage.[12] It also strengthens tight junction proteins including ZO-1 and claudin, directly reducing gut permeability and LPS translocation. You can read more about the clinical evidence for Lactobacillus plantarum in our dedicated guide.
Bifidobacterium longum — The NASH Synbiotic Partner
Bifidobacterium longum is among the most studied Bifidobacterium species for liver disease, particularly in combination with prebiotic substrates. A landmark RCT by Malaguarnera et al. demonstrated that B. longum combined with fructooligosaccharides in patients with nonalcoholic steatohepatitis (NASH) significantly reduced serum LPS (endotoxemia), improved liver enzyme profiles, and reduced hepatic steatosis.[13] B. longum also produces spermidine — a metabolite that can enter the liver via blood circulation, activate CD4+ T-cell immunity through autophagy, and increase IFN-γ expression — providing an immune-modulatory mechanism beyond barrier repair.[12] Learn more about the food sources and supplemental research for Bifidobacterium longum.
Bifidobacterium bifidum — Anti-Inflammatory Macrophage Modulator
Bifidobacterium bifidum has been shown to promote the transformation of Kupffer cells (liver-resident macrophages) from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype in cirrhotic patients — directly modulating the hepatic immune environment in a way that could reduce liver inflammation independent of the gut barrier mechanism.[6] In the pioneering Kirpich study of alcohol-induced liver injury, B. bifidum combined with L. plantarum 8PA3 significantly increased fecal Bifidobacteria and Lactobacilli and lowered liver enzymes compared to standard therapy.[8] For more on what Bifidobacterium bifidum deficiency looks like and why this species matters, see our related article.
Streptococcus thermophilus — Liver Enzyme Reduction in NAFLD
Streptococcus thermophilus combined with Lactobacillus delbrueckii subsp. bulgaricus — both present in MicroBiome Restore — was evaluated in a double-blind RCT in NAFLD patients. Daily consumption significantly alleviated liver aminotransferase (ALT) blood levels, providing clinical validation for this combination specifically in the NAFLD context.[11] Our dedicated guide to Streptococcus thermophilus benefits covers the broader clinical evidence for this often-underappreciated strain.
Lactobacillus acidophilus — Antioxidant and Spermidine Precursor
L. acidophilus is a key producer of spermidine — alongside B. longum and Enterococcus faecalis — a polyamine metabolite that activates anti-tumor and immune-regulatory processes in the liver by promoting autophagy in CD4+ T cells.[12] It is also among the strains shown to reduce hepatic TNF and TLR4 expression in experimental ALD models.[10] As a native resident of the gut with broad antimicrobial and barrier-supporting activity, it contributes to the composite liver-protective effect of multi-strain supplementation. Our article on Lactobacillus acidophilus dosing and clinical guidelines provides the full evidence base for this strain.
Lactobacillus casei — Liver Lipid Metabolism and ALD
L. casei strain Shirota, administered for 60 days in patients with alcohol-induced liver injury, repleted fecal Bifidobacteria and Lactobacilli abundances and improved serum triglyceride and LDL cholesterol levels, while reducing inflammatory markers.[12] L. casei is one of the strains included in the VSL#3 combination that has been studied in cirrhosis and alcohol-related liver disease, contributing to the documented improvements in hepatic encephalopathy reversal and MELD score reduction seen with that multi-strain formula.
Lactobacillus paracasei — Alcoholic Liver Injury and Gut Microbiome Restoration
Lactobacillus paracasei CCFM1120 has demonstrated beneficial effects against alcoholic liver disease in preclinical models, reinforcing its candidacy as part of a comprehensive multi-strain liver support formula.[12] In the broader context of gut microbiome restoration for liver health, L. paracasei is valued for its colonization capacity and its bile acid tolerance, which enables it to persist in the gut environment and exert sustained prebiotic and barrier-supporting effects.
Bacillus subtilis — LPS Reduction in Alcoholic Hepatitis
Among the Bacillus strains in MicroBiome Restore, Bacillus subtilis combined with Enterococcus faecium has been specifically studied in patients with alcoholic hepatitis, demonstrating a reduction in serum LPS levels alongside restoration of the gut microbiota.[10] Bacillus species produce spore-forming structures that allow them to survive gastric transit more reliably than many non-spore-forming probiotic bacteria, making them particularly well-suited for gut colonization in the setting of a disrupted intestinal environment. Our article on Bacillus subtilis probiotic benefits covers the evidence for this strain in detail.
All of These Strains. One Filler-Free Formula.
MicroBiome Restore contains every strain discussed in this article — plus additional evidence-backed species — with 15 billion CFU per serving, 7 certified organic prebiotics, and zero fillers like microcrystalline cellulose or magnesium stearate.
| Strain (in MicroBiome Restore) | Primary Liver-Health Mechanism | Key Evidence |
|---|---|---|
| L. rhamnosus | Tight junction reinforcement, LPS reduction, TNF-α suppression | ALT reduction in pediatric NAFLD; reduces endotoxemia and liver injury in ALD[9] |
| L. plantarum | Antioxidant (SOD/GSH elevation), barrier repair, LPS displacement | Significant ALT/AST/GGT/LDH reduction vs. standard therapy in ALD RCT[8] |
| B. longum | LPS reduction, steatosis improvement, spermidine production | Synbiotic combo reduced serum LPS and liver enzymes in NASH RCT[13] |
| B. bifidum | M1→M2 macrophage polarization, gut flora restoration | Reduced liver enzymes in ALD; macrophage modulation in cirrhosis[8] |
| S. thermophilus | Aminotransferase reduction | Significant ALT reduction in NAFLD double-blind RCT (with L. bulgaricus)[11] |
| L. acidophilus | TLR4/TNF-α suppression, spermidine precursor, barrier support | Reduces hepatic TNF and TLR4 in experimental ALD; spermidine immune activation[10] |
| L. casei | Lipid metabolism improvement, microbiome restoration | Improved TG, LDL, and gut flora in ALD patients (strain Shirota, 60 days)[12] |
| B. subtilis | Serum LPS reduction, spore-forming gastric survival | LPS reduction + microbiota restoration in alcoholic hepatitis patients[10] |
Probiotics for Liver Cirrhosis: What the Evidence Shows
Cirrhosis is the end stage of progressive liver fibrosis — a state in which scar tissue replaces functional liver parenchyma, compromising the liver's ability to perform its essential roles. The gut-liver axis is severely disrupted in cirrhotic patients: intestinal permeability increases substantially, gut-derived endotoxemia worsens, and the microbial community shifts dramatically toward a pathogen-dominant state.[7]
A 2024 systematic review and meta-analysis by Yang et al. — the most comprehensive analysis of probiotics in cirrhosis to date, including 30 randomized controlled trials — found that probiotic supplementation significantly reversed minimal hepatic encephalopathy (MHE) (RR 1.54; 95% CI 1.03–2.32) and improved established hepatic encephalopathy (RR 1.94; 95% CI 1.24–3.06).[6] Multi-strain formulas containing Streptococcus, Bifidobacterium, and Lactobacillus together showed more significant HE improvement than single-strain products (RR 1.44), reinforcing the rationale for comprehensive multi-strain supplementation.[6]
A separate 2024 meta-analysis of 22 RCTs in cirrhosis found that probiotics significantly reduced GGT (effect size: 0.307; p = 0.024), AST (p = 0.013), serum ammonia (effect size: −1.093; p < 0.001), and endotoxin levels (effect size: −0.961; p < 0.001), while improving quality-of-life scores.[3] Ammonia and endotoxin reduction are particularly clinically meaningful, as elevated blood ammonia is the primary driver of hepatic encephalopathy, and endotoxemia drives systemic inflammation and further liver damage.
A 2022 meta-analysis examining gut microbiome composition in cirrhosis and the effects of probiotic therapy found that Lactobacillus counts were significantly increased following supplementation (SMD 0.63; 95% CI 0.12–1.15), and that blood ammonia and the incidence of hepatic encephalopathy were significantly reduced in the probiotic group — with an effect comparable to lactulose (the standard pharmacological treatment for HE), but with a substantially better tolerability profile.[14]
Important Note for Cirrhosis Patients
While the evidence for probiotic supplementation in cirrhosis is encouraging, liver cirrhosis is a serious medical condition that requires ongoing management by a qualified hepatologist or gastroenterologist. Probiotics should be considered a supportive adjunct — not a replacement for medical treatment. If you have cirrhosis, always consult your physician before starting any new supplement.
For cirrhosis-related complications beyond HE — including spontaneous bacterial peritonitis (SBP) and overall mortality — the current evidence is less definitive, and more high-quality trials are needed. That said, the consistent finding that probiotics reduce endotoxemia and improve the microbiome signature of cirrhosis, alongside strong safety data, makes them a reasonable consideration as part of an integrated management strategy.
Probiotics for Alcohol-Associated Liver Disease
Alcohol-associated liver disease (ALD) encompasses a spectrum from early steatosis (fatty liver from alcohol) through alcoholic hepatitis to cirrhosis. Alcohol's toxic effects on the gut are well-documented: ethanol directly damages intestinal tight junctions, increases gut permeability, promotes Gram-negative bacterial overgrowth, and drives endotoxemia that reaches the liver via the portal vein.[15]
The clinical evidence for probiotics in ALD begins with a landmark pilot study by Kirpich et al. in 66 patients with alcohol-induced liver injury. After just 5 days of supplementation with Bifidobacterium bifidum and Lactobacillus plantarum 8PA3, the probiotic group showed significantly lower ALT and AST compared to standard therapy (AST: 54.67 vs. 76.43 U/L; ALT: 36.69 vs. 51.26 U/L). In patients with well-characterized mild alcoholic hepatitis, the probiotic arm achieved significant end-of-treatment reductions in ALT, AST, GGT, LDH, and total bilirubin — a comprehensive panel of liver injury markers.[8]
A 2024 systematic review and meta-analysis of probiotics in ALD found that, following probiotic treatment, Gram-negative bacteria such as E. coli decreased while Bifidobacterium and Lactobacillus populations increased across all 7 included studies reporting microbiome outcomes — demonstrating consistent microbiome-normalizing effects.[15] The analysis found significant improvements in liver function markers including ALT, AST, and total bilirubin, with good safety profiles across trials.
Lactobacillus subtilis and Enterococcus faecium: An Underappreciated Pairing
A clinically notable finding in the ALD literature involves Bacillus subtilis combined with Enterococcus faecium — both present in MicroBiome Restore. In patients with alcoholic hepatitis, this combination specifically decreased serum LPS levels alongside gut microbiota restoration.[10] Given that LPS-driven TLR4 activation is the central pathway by which gut-derived signals cause liver inflammation in ALD, this represents a mechanistically relevant finding. The spore-forming capacity of Bacillus species also gives them a practical advantage: they survive gastric transit and the disrupted intestinal environment more reliably than many non-spore-forming strains.
The broader mechanistic research on L. rhamnosus GG in ALD is particularly instructive. Wang et al. demonstrated that LGG potentiates intestinal hypoxia-inducible factor (HIF) — a transcription factor that upregulates tight junction proteins under the hypoxic conditions created by alcohol — and thereby promotes intestinal integrity and ameliorates alcohol-induced liver injury.[16] This is one of the most elegant demonstrations of a direct mechanistic link between probiotic supplementation and hepatic protection, involving a pathway (intestinal HIF-1α) not previously recognized as a probiotic target.
The question of whether someone who continues to drink alcohol should take probiotics is nuanced. The evidence suggests probiotics can reduce alcohol-related liver damage when drinking continues — but this should never be interpreted as a license for unsafe drinking. Abstinence from alcohol is the most effective intervention for ALD at every stage.
What About NAFLD and Fatty Liver? A Brief Overview
👉 Full NAFLD Article Coming Soon
The evidence base for probiotics in nonalcoholic fatty liver disease is extensive enough to warrant its own dedicated article, and we'll be publishing that guide shortly. It will cover NAFLD-specific RCT data in depth, strain dosing for steatosis reduction, evidence on fibrosis markers, and what the most recent meta-analyses (including 41-RCT pooled analyses) show for synbiotic vs. probiotic-only approaches. For now, here's a concise orientation to the key findings.
Nonalcoholic fatty liver disease is the most common chronic liver disease worldwide, affecting approximately 25% of the global population. Its progression — from simple hepatic steatosis through NASH to fibrosis and cirrhosis — is closely tied to gut microbiome composition, intestinal permeability, and endotoxemia.[4]
The bulk of the clinical trial evidence for probiotics in liver disease is concentrated in NAFLD, and the results are encouraging. A 2024 systematic review and meta-analysis of 34 double-blind RCTs found that probiotics, prebiotics, and synbiotics all significantly improved liver enzyme levels, reduced steatosis on imaging, and improved fibrosis scores, with synbiotics showing the most consistent effects on the broadest range of outcomes.[17] Specifically, synbiotic supplementation reduced ALT (SMD: −0.48), AST (SMD: −0.35), TNF-α (SMD: −0.86), and HOMA-IR (SMD: −0.28) compared to placebo — all statistically significant.[5]
The strains most consistently associated with positive outcomes in NAFLD include L. rhamnosus (GG strain), L. delbrueckii subsp. bulgaricus + Streptococcus thermophilus (ALT reduction in a double-blind RCT), B. longum (endotoxemia reduction with FOS synbiotic), and multi-strain combinations including L. rhamnosus, L. casei, L. plantarum, B. longum, and Streptococcus thermophilus.[4] All of these are present in MicroBiome Restore.
An important nuance: the synbiotic advantage in NAFLD is likely not coincidental. Providing prebiotic substrates alongside probiotic bacteria creates conditions for more durable colonization and higher SCFA production — particularly butyrate, which is a critical fuel for colonocytes and a direct inhibitor of hepatic lipogenesis. MicroBiome Restore's prebiotic matrix — including Jerusalem artichoke (a concentrated inulin source that selectively feeds Lactobacillus and Bifidobacterium), acacia fiber, and maitake mushroom beta-glucan — provides this functional substrate alongside its 26 probiotic strains, making it an inherently synbiotic product in its mechanism of action.
For more on how probiotics influence cholesterol and lipid metabolism — closely related to NAFLD pathophysiology — and how probiotics affect type 2 diabetes and blood sugar (the primary metabolic driver of NAFLD progression), those dedicated articles are available in the Gut Check blog.
How to Choose a Probiotic for Liver Health Support
The supplement market for probiotics is poorly regulated, and the gap between what's claimed on labels and what's supported by evidence is substantial. Here is what actually matters when evaluating a probiotic for liver health.
Multi-Strain Formulas Are Not Optional
The liver-protective mechanisms of probiotic supplementation operate through multiple pathways simultaneously — barrier reinforcement, LPS reduction, SCFA production, bile acid modulation, ammonia metabolism. No single strain addresses all of these. The most consistently effective products in liver disease trials — including VSL#3, which contains 8 different bacterial strains — and the best-performing combinations across NAFLD, cirrhosis, and ALD studies all use multi-strain approaches.[6] A single-strain product claiming liver benefits should be viewed skeptically.
Prebiotic Support Matters Enormously in a Liver Health Context
The synbiotic advantage in NAFLD trials is a consistent finding in the literature — and the reason is mechanistically clear. Prebiotics feed the probiotic bacteria you're supplementing, enabling better colonization and higher SCFA production. They also independently reduce gut permeability and LPS translocation by feeding the beneficial bacteria already resident in your gut. MicroBiome Restore includes Jerusalem artichoke — a concentrated source of inulin that selectively promotes Lactobacillus and Bifidobacterium growth — alongside acacia fiber, maitake mushroom beta-glucan, fig fruit, bladderwrack, Norwegian kelp, and oarweed. This prebiotic matrix functions as a complete ecosystem support system for the 26 probiotic strains in the formula.
Fillers Can Undermine the Point
If you're taking a probiotic specifically to support the gut-liver axis, adding compounds that have documented effects on the gut microbiome or intestinal permeability doesn't make sense. Microcrystalline cellulose (MCC), magnesium stearate, and silicon dioxide are standard manufacturing additives with no biological benefit to you. MicroBiome Restore uses none of these — every ingredient in the formula is there because it does something for your microbiome.
Capsule Quality and Strain Stability
Most probiotics use hypromellose (HPMC) capsules — a synthetic cellulose-based polymer. MicroBiome Restore uses pullulan capsules — fermented from tapioca, with prebiotic properties — as part of its organic prebiotic matrix. The capsule itself feeds beneficial bacteria rather than simply carrying them. The 26 strains are lyophilized with maltodextrin as a cryoprotectant (a standard, well-studied stabilization method that maintains CFU viability), not used as a filler. You can learn how to read probiotic labels accurately in our dedicated guide.
What to Look for vs. What to Avoid
Look for: Multi-strain formula with named Lactobacillus and Bifidobacterium species clinically studied for liver outcomes (L. rhamnosus, L. plantarum, L. acidophilus, B. longum, B. bifidum); accompanying prebiotic substrates (synbiotic formulation); clearly disclosed CFU count per serving; filler-free formulation; quality capsule material; Bacillus species for spore-forming stability if gut environment is heavily disrupted.
Avoid: Single-strain products; formulas with microcrystalline cellulose, magnesium stearate, or titanium dioxide in inactive ingredients; proprietary blends that obscure individual strain doses; brands that make explicit health claims about "treating" or "curing" liver disease (regulatory red flag and scientifically unfounded); products without published CFU counts.
26 Strains. 7 Certified Organic Prebiotics. Zero Fillers.
MicroBiome Restore was formulated around a single principle: every ingredient earns its place through biological function. The result is a 26-strain, filler-free synbiotic with 15 billion CFU per serving, including every key Lactobacillus and Bifidobacterium species discussed throughout this article.
Frequently Asked Questions
Can probiotics reverse liver damage?
The evidence does not support a claim that probiotics reverse established structural liver damage — particularly fibrosis or cirrhosis, where scar tissue has already replaced functional liver tissue. What the clinical evidence does support is that probiotics can reduce the ongoing drivers of liver injury: endotoxemia, hepatic inflammation, oxidative stress, and ammonia load. By addressing these, probiotics may slow progression and, in early stages like NAFLD, some studies have documented improvements in steatosis grade on imaging following synbiotic supplementation. This is a meaningful clinical benefit, but not the same as reversal of structural damage.
What is the best probiotic for liver health?
Based on the current evidence, the most effective approach involves a multi-strain probiotic that includes Lactobacillus rhamnosus, Lactobacillus plantarum, Bifidobacterium longum, Bifidobacterium bifidum, and Streptococcus thermophilus — ideally combined with prebiotic substrates (a synbiotic formula). No single strain is the "best" — the protective effects operate through multiple mechanisms that different strains address differently. For more guidance on selecting among formulas, our article on how to increase butyrate and SCFAs covers the prebiotic side of the equation.
Can SIBO affect the liver?
Yes — and significantly so. Small intestinal bacterial overgrowth (SIBO) is closely associated with increased intestinal permeability and elevated portal endotoxemia. Excess bacteria in the small intestine ferment substrates improperly, produce higher concentrations of LPS and other inflammatory metabolites, and compromise the tight junction integrity of the small intestinal epithelium — all of which translate into increased hepatic inflammation and accelerated liver disease progression. Probiotic supplementation is one of the evidence-backed interventions for restoring small intestinal microbial balance. Our guide to probiotics for SIBO covers the specific strains and clinical evidence in depth.
How long does it take for probiotics to affect liver enzyme levels?
Most RCTs showing significant reductions in ALT and AST used intervention periods of 8 to 24 weeks. The Kirpich alcohol-related liver injury study showed significant enzyme reductions after just 5 days of supplementation — though that was a high-dose short-term intervention. For NAFLD and cirrhosis, typical trial durations range from 12 to 24 weeks before statistically significant enzyme improvements are documented. Consistent daily supplementation over this period is essential, as the microbiome-normalizing effects take time to establish and are not sustained without ongoing support.
Should someone with alcoholic liver disease take probiotics?
The clinical evidence suggests probiotics can reduce alcohol-related liver injury — specifically by addressing the endotoxemia and dysbiosis that alcohol causes. The Kirpich study found meaningful liver enzyme improvements after just 5 days in patients with established liver injury. That said, liver disease from alcohol is a serious medical condition that requires physician oversight. Probiotics are a supportive adjunct, not a substitute for medical care or for the most effective intervention — reducing alcohol consumption. Anyone with known alcoholic liver disease should discuss probiotic supplementation with their hepatologist before starting.
How do probiotics connect to other aspects of metabolic health that affect the liver?
Liver health sits at the intersection of several metabolic processes where probiotics have demonstrated effects: blood sugar regulation, cholesterol and lipid metabolism, body weight, and systemic inflammation. NAFLD in particular is driven by insulin resistance and dyslipidemia — and probiotics have shown measurable effects on HOMA-IR (insulin resistance index), LDL cholesterol, and TNF-α across multiple trials. For related reading, our articles on probiotics and metabolism, probiotics for belly fat, and probiotics for type 2 diabetes and blood sugar explore these interconnections.
References
- Chen, B., Fu, S., Peng, K., et al. (2025). The gut-liver axis: Molecular mechanisms and therapeutic targeting in liver disease. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12716074/
- Cao, C., Shi, M., Wang, X., Yao, Y., & Zeng, R. (2023). Effects of probiotics on non-alcoholic fatty liver disease: A review of human clinical trials. Frontiers in Nutrition, 10, 1155306. https://doi.org/10.3389/fnut.2023.1155306
- Dajani, A., Nassif, S., et al. (2024). Efficacy of probiotics on improvement of health outcomes in cirrhotic liver disease patients: A systematic review and meta-analysis of randomised controlled trials. European Journal of Pharmacology. https://www.sciencedirect.com/science/article/pii/S0014299924005636
- Kaufmann, B., Seyfrid, N., Hartmann, D., & Hartmann, P. (2023). Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. American Journal of Physiology-Gastrointestinal and Liver Physiology, 325, G42–G61. https://doi.org/10.1152/ajpgi.00017.2023
- Reza, Z., Barbalho, S. M., et al. (2024). Efficacy of synbiotics in the management of non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Population Therapeutics and Clinical Pharmacology. https://www.jptcp.com/index.php/jptcp/article/view/10734
- Yang, X., Lei, L., Shi, W., Li, X., Huang, X., Lan, L., Lin, J., Liang, Q., Li, W., & Yang, J. (2024). Probiotics are beneficial for liver cirrhosis: A systematic review and meta-analysis of randomized control trials. Frontiers in Medicine, 11, 1379333. https://doi.org/10.3389/fmed.2024.1379333
- Vlachogiannakos, J., & Saveriadis, A. (2025). A systematic review of microbiota in cirrhosis: A change towards a more pathogenic predisposition. International Journal of Molecular Sciences, 26(2), 527. https://doi.org/10.3390/ijms26020527
- Kirpich, I. A., Solovieva, N. V., Leikhter, S. N., et al. (2008). Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: A pilot study. Alcohol, 42(8), 675–682. https://pmc.ncbi.nlm.nih.gov/articles/PMC2630703/
- Wang, Y., Kirpich, I., Liu, Y., et al. (2011). Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. The American Journal of Pathology, 179(6), 2866–2875. https://doi.org/10.1016/j.ajpath.2011.08.039
- Kaufmann, B., Seyfrid, N., Hartmann, D., & Hartmann, P. (2023). Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. American Journal of Physiology-Gastrointestinal and Liver Physiology, 325, G42–G61 (Table 1, ALD studies). https://pmc.ncbi.nlm.nih.gov/articles/PMC10312326/
- Aller, R., De Luis, D. A., Izaola, O., et al. (2011). Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. European Review for Medical and Pharmacological Sciences, 15(9), 1090–1095. As cited in: Frontiers in Gastroenterology NAFLD review (2024). https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2024.1534431/full
- Li, X., Niu, B., Feng, Y., et al. (2025). Crucial functions of gut microbiota on gut–liver repair. ScienceDirect. https://www.sciencedirect.com/science/article/pii/S294992832500001X
- Malaguarnera, M., Vacante, M., Antic, T., et al. (2012). Bifidobacterium longum with fructo-oligosaccharides in patients with non-alcoholic steatohepatitis. Digestive Diseases and Sciences, 57(2), 545–553. https://doi.org/10.1007/s10620-011-1887-4
- Liu, J., Luo, M., He, H., & Peng, B. (2022). Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: A systematic review and meta-analysis. PubMed. https://pubmed.ncbi.nlm.nih.gov/36595801/
- Fang, C., Cheng, J., Jia, W., & Xu, Y. (2024). Clinical efficacy of probiotics in the treatment of alcoholic liver disease: A systematic review and meta-analysis. Frontiers in Cellular and Infection Microbiology, 14, 1358063. https://pmc.ncbi.nlm.nih.gov/articles/PMC10964906/
- Wang, Y., Kirpich, I., Liu, Y., et al. (2011). Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. The American Journal of Pathology, 179(6), 2866–2875. https://pubmed.ncbi.nlm.nih.gov/22093263/
- Pan, Y., Yang, Y., Wu, J., Zhou, H., & Yang, C. (2024). Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. BMC Gastroenterology, 24(1), 283. https://pmc.ncbi.nlm.nih.gov/articles/PMC11342484/
Ready to Support Your Liver from the Inside Out?
MicroBiome Restore delivers 26 probiotic strains — including every key Lactobacillus and Bifidobacterium species discussed in this article — alongside 7 certified organic prebiotic substrates. Filler-free. 15 billion CFU. Formulated without microcrystalline cellulose, magnesium stearate, or any manufacturing aids that don't belong in a product built around microbial health.
'%3e%3cg%20id='Final-Copy-2_2_'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st0'%20d='M7.4,12.8h6.8l3.1-11.6H7.4C4.2,1.2,1.6,3.8,1.6,7S4.2,12.8,7.4,12.8z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3cg%20id='final---dec.11-2020'%3e%3cg%20id='_x30_208-our-toggle'%20transform='translate(-1275.000000,%20-200.000000)'%3e%3cg%20id='Final-Copy-2'%20transform='translate(1275.000000,%20200.000000)'%3e%3cpath%20class='st1'%20d='M22.6,0H7.4c-3.9,0-7,3.1-7,7s3.1,7,7,7h15.2c3.9,0,7-3.1,7-7S26.4,0,22.6,0z%20M1.6,7c0-3.2,2.6-5.8,5.8-5.8%20h9.9l-3.1,11.6H7.4C4.2,12.8,1.6,10.2,1.6,7z'/%3e%3cpath%20id='x'%20class='st2'%20d='M24.6,4c0.2,0.2,0.2,0.6,0,0.8l0,0L22.5,7l2.2,2.2c0.2,0.2,0.2,0.6,0,0.8c-0.2,0.2-0.6,0.2-0.8,0%20l0,0l-2.2-2.2L19.5,10c-0.2,0.2-0.6,0.2-0.8,0c-0.2-0.2-0.2-0.6,0-0.8l0,0L20.8,7l-2.2-2.2c-0.2-0.2-0.2-0.6,0-0.8%20c0.2-0.2,0.6-0.2,0.8,0l0,0l2.2,2.2L23.8,4C24,3.8,24.4,3.8,24.6,4z'/%3e%3cpath%20id='y'%20class='st3'%20d='M12.7,4.1c0.2,0.2,0.3,0.6,0.1,0.8l0,0L8.6,9.8C8.5,9.9,8.4,10,8.3,10c-0.2,0.1-0.5,0.1-0.7-0.1l0,0%20L5.4,7.7c-0.2-0.2-0.2-0.6,0-0.8c0.2-0.2,0.6-0.2,0.8,0l0,0L8,8.6l3.8-4.5C12,3.9,12.4,3.9,12.7,4.1z'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Your Privacy Choices
Share and get 15% off!
Simply share this product on one of the following social networks and you will unlock 15% off!